Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04762979 |
| Title | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Amanda Parkes |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Illinois Cancer Center | RECRUITING | Chicago | Illinois | 60612 | United States | Details |
| University of Nebraska Medical Center | RECRUITING | Omaha | Nebraska | 68198 | United States | Details |
| Penn State Cancer Institute | RECRUITING | Hershey | Pennsylvania | 17033 | United States | Details |
| University of Wisconsin | ACTIVE_NOT_RECRUITING | Madison | Wisconsin | 53705 | United States | Details |